Radionuclide therapy targeting prostate-specific membrane antigen (PSMA) is promising for
prostate cancer. We previously reported a ligand, 64Cu-CuSarbisPSMA, featuring 2 lysine …

361 Objectives [123 I] MIP-1072,(S)-2-(3-((S)-1-carboxy-5-(4-[123 I] iodobenzylamino)
pentyl) ureido) pentanedioic acid is a high affinity ligand for PSMA (Can Res 2009) which …

170 Objectives [123 I] MIP-1095,(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl) ureido) pentyl)
ureido) pentanedioic acid, a high affinity ligand for PSMA (Can Res 2009), has been shown …

Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer, and
small-molecule radiopharmaceuticals targeting PSMA rapidly detect the location and extent …

Purpose: Prostate-specific membrane antigen (PSMA) is a cell surface protein that is
overexpressed in prostate cancer, including hormone-refractory and metastatic disease. Our …

Prostate-specific membrane antigen (PSMA) is a well-established target for developing
radiopharmaceuticals for imaging and therapy of prostate cancer (PCa). We have recently …

Despite significant gains in the treatment of metastatic castration-resistant prostate cancer by
radioligands targeting prostate-specific membrane antigen (PSMA), 30% of patients never …

Prostate-specific membrane antigen (PSMA) theranostics have been introduced with 68Ga
and 177Lu, the most used radionuclides. However, 188Re is a well-known generator-based …

Despite significant research activities and subsequent progress made in the fight against
cancer over the last few decades, prostate cancer remains a major health-related problem …

Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis and
radionuclide therapy of prostate cancer. This study reports conversion of a previously …